Please assess the completion status of the following clinical trial:

Trial Title: Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Exploratory Cognitively Healthy Subjects~* ≥ 20 to ≤ 40 years of age OR ≥ 50 years of age~* Mini-mental state examination (MMSE) ≥ 29~* No significant history of cognitive impairment~Exploratory MCI Subjects~* ≥ 50 years of age~* MMSE ≥ 24~* Have MCI consistent with National Institute on Aging-Alzheimer's Association (NIA-AA) working group's diagnostic guidelines for AD~* Have a study partner that can report on subject's activities of daily living~Exploratory AD Subjects~* ≥ 50 years of age~* MMSE \> 10~* Have possible or probable AD based on the NIA-AA working group's diagnostic guidelines for AD~* Have a study partner that can report on subject's activities of daily living~Confirmatory Subjects~* ≥ 50 years of age~* MMSE ≥ 20 and ≤ 27~* Cognitively impaired subjects with either MCI or dementia with a suspected neurodegenerative cause~* Have a study partner that can report on subject's activities of daily living~Exclusion Criteria:~* Current clinically significant psychiatric disease~* Evidence of structural brain abnormalities~* History of moderate or severe traumatic brain injury~* Current clinically significant cardiovascular disease or ECG abnormalities, or additional risk factors for Torsades de Pointes~* Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer~* History of alcohol or substance abuse or dependence~* Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception~* Have received or participated in a trial with investigational medications in the past 30 days~* Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Exploratory Cognitively Healthy Subjects (Type: EXPERIMENTAL): Subjects will receive an IV injection, 370 megabecquerel (MBq) (10 millicurie \[mCi\]), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline.
- Exploratory MCI Subjects (Type: EXPERIMENTAL): Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.
- Exploratory AD Subjects (Type: EXPERIMENTAL): Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.
- Confirmatory Subjects (Type: EXPERIMENTAL): Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 and flortaucipir at baseline.

Based on this trial design, predict the completion outcome and termination type (if applicable).